The Centre for the Commercialization of Antibodies and Biologics has named Robert Verhagen as its new CEO. In this new position, Verhagen is expected to steer CCAB as a leader in the commercialization of academic discoveries in biologics and position it at the forefront of biotech advancement in Canada. Verhagen has more than 20 years of business and executive experience in pharmaceuticals and diagnostics. After carrying out the reorganization of Helix Pharma when he was its CEO, Verhagen raised $30 million and advanced its lung cancer drug candidate through early stage clinical trials. He sits on the portfolio development committee for Innovate Calgary, providing due diligence and advice to early-stage companies engaged in the development of new technology, from life sciences to cleantech. Verhagen held executive or senior management roles at Spectral Medical Inc, MDS Inc, and founded INH Technologies Inc.
Robert Verhagen, CEO, Centre for the Commercialization of Antibodies and Biologics